GlassScriptPhysician profile
Ronald A Charles
NPI 1447427661
$4,804.47
in general payments reported to CMS, 2019-2025
13 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $163 · 2021: $138 · 2022: $64.83 · 2023: $3,810 · 2024: $110 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,004 · Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,004.05 |
| Food and Beverage | $745.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,725.03 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Eisai INC. | $221.04 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.58 | 2020-2025 | Gattex, Livtencity |
| Abbvie INC. | $183.42 | 2019-2021 | |
| Gilead Sciences, INC. | $164.27 | 2020-2021 | |
| Tela Bio, INC. | $139.41 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Shire North American Group INC | $63.83 | 2019 | |
| Madrigal Pharmaceuticals | $32.85 | 2025 | Rezdiffra |
| Genentech USA, INC. | $20.38 | 2024 | Tecentriq, Avastin |
| Ethicon US, LLC | $16.67 | 2022 | |
| Exelixis INC. | $15.00 | 2025 | Cabometyx |
| Integra Lifesciences Corporation | $14.31 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.